Strategic divestiture Surmodics recently completed the sale of assets to Endologix in May 2026, signaling a potential reallocation of strategic priorities and an openness to partnerships or opportunistic collaborations to address existing product gaps or new vascular device opportunities.

Thrombectomy growth The introduction and full commercial release of the Pounce XL thrombectomy system, along with prior Pounce offerings, indicate a strong emphasis on clot retrieval technologies, presenting sales opportunities with hospitals and interventional centers seeking advanced thrombectomy solutions.

PROWL data leverage PROWL registry studies with real-world thrombotic limb ischemia data and sex-specific analyses are being showcased at major conferences, suggesting opportunities to engage researchers and clinical teams for clinical support, training, and co-development discussions around evidence-based device adoption.

IIVD and surface tech Surmodics’ leadership in surface modification for intravascular devices and its role as a supplier of immunoassay components and microarrays positions the company for cross-selling with manufacturers needing surface coatings, chemical components, and diagnostic assay materials.

Geographic expansion With manufacturing expansion to Ireland and Northern Europe, there are regional sales opportunities to align with localized demand, provide regional service and support, and collaborate on supply chain resilience for European customers.